432 filings
Page 4 of 22
SC TO-T/A
b6k89l
17 May 12
Third party tender offer statement (amended)
12:00am
8-A12B
kgjfcp
17 May 12
Registration of securities on exchange
12:00am
SC 14D9
87zri
17 May 12
Tender offer solicitation
12:00am
8-K
isq8u
17 May 12
Human Genome Sciences Announces Adoption of
12:00am
8-K
ag9mza77
16 May 12
Submission of Matters to a Vote of Security Holders
12:00am
SC14D9C
s05chu6
10 May 12
Written communication relating to third party tender offer
12:00am
SC TO-T
uirejvla 2f96h
10 May 12
Third party tender offer statement
12:00am
SC TO-C
thn8 x7x3olvl
9 May 12
Information about tender offer
12:00am
8-K
kec390vl ydb
24 Apr 12
Results of Operations and Financial Condition
12:00am
8-K
9s2g2aezu
19 Apr 12
Human Genome Sciences Announces Unsolicited Offer from Glaxosmithkline; HGS Board of Directors Authorizes Exploration of Strategic Alternatives
12:00am
DEFA14A
8ccxtmbkik33f xe
30 Mar 12
Additional proxy soliciting materials
12:00am
8-K
ltnqj3e31q0gx6v46
27 Feb 12
Results of Operations and Financial Condition
12:00am
8-K
z4kjvgbin 5f8tpoxya
9 Jan 12
Human Genome Sciences Reports Progress with Commercialization of Benlysta® and Announces 2012 Goals at Jpmorgan Healthcare Conference
12:00am
8-K
on3hvn
16 Nov 11
GSK receives initial data from the first completed phase III study of albiglutide in type 2 diabetes
12:00am
8-K
w4n8u8xtj6ma9i
10 Nov 11
Regulation FD Disclosure
12:00am
8-K
i1f0cxpl6plpm
7 Nov 11
Entry into a Material Definitive Agreement
12:00am
424B5
pewhtca9254svm2epyyq
4 Nov 11
Prospectus supplement for primary offering
12:00am